|
Jun 20
|
Madrigal poised to enter European MASH market after CHMP endorsement
|
|
Jun 20
|
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
|
|
Jun 17
|
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 12
|
Exploring High Growth Tech Stocks In The US Market
|
|
Feb 28
|
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA
|
|
Feb 27
|
We're Not Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn
|
|
Feb 27
|
High Growth Tech Stocks In US For February 2025
|
|
Feb 27
|
Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...
|
|
Feb 27
|
Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call
|
|
Feb 26
|
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
|
|
Feb 26
|
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
|
|
Feb 26
|
Why Madrigal Pharmaceuticals Stock Is Soaring Today
|
|
Feb 26
|
Madrigal: Q4 Earnings Snapshot
|
|
Feb 26
|
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
|
|
Feb 26
|
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
|
|
Feb 12
|
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
|